Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap6.87B
Enterprise Value7.63B
P/E Ratio70.83
PEG Ratio-1.28
Price/Sales Ratio2.42
Price/Book Ratio1.13
Enterprise/Revenue2.7
Enterprise/EBITDA30.1

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterSeptember 30, 2026

Profitability

Profit Margin0.04
Operating Margin0.09
AD

Management Effectiveness

Return On Assets0.01
Return On Equity0.02

Income Statement

Revenue5.48B
Revenue/Share3.46
Gross Profit1.74B
EBITDA846.59M
Net Income349.49M
Diluted EPS0.24

Balance Sheet

Total Cash4.27B
Total Cash/Share3.1
Total Debt2.86B
Total Debt/Equity0.24
Current Ratio2.34
Book Value Per Share8.24

Price History

52-Week Change-27.4
52-Week High5.77
52-Week Low3.74
Moving Average 50 Days4.01
Moving Average 200 Days4.52

Statistics

Average Volume527,563
Shares Outstanding3.38B
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0.14
Trailing Annual Dividend Yield1.57
Payout Ratio1.35
Last Split FactorN/A
Last Split DateN/A
AD